Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| MOTS-c | Semaglutide | |
|---|---|---|
| Category | Peptides | Pharmaceuticals |
| Standard Dose | Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection. | Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily. |
| Timing | Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance. | SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications. |
| Cycle Duration | 8-16 week cycles. | Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials). |
| Evidence Level | Emerging (strong preclinical) | Strong (FDA-approved) |
MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.
Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.
Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.
8-16 week cycles.
Semaglutide is a GLP-1 receptor agonist with 94% structural homology to native GLP-1, modified with amino acid substitutions and a C-18 fatty acid chain that enables albumin binding, extending half-life to approximately 7 days. Centrally, it activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons in the arcuate nucleus of the hypothalamus, reducing hunger and increasing satiety. Peripherally, it slows gastric emptying, enhances glucose-dependent insulin secretion from pancreatic beta-cells, and reduces glucagon secretion, providing comprehensive metabolic regulation.
Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily.
SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications.
Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →